# HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

> **NCT02525302** · PHASE2 · TERMINATED · sponsor: **Akashi Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** HT-100

## Key facts

- **NCT ID:** NCT02525302
- **Lead sponsor:** Akashi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-12-30
- **Final completion:** 2016-12-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Dosing stopped
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525302, "HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02525302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*